Pharmasset News
Most Popular Pharmasset Story
Gilead shares surge as hep C drug scores a cure for big patient population
Gilead Sciences ($GILD) received its first bonus from the monster $10.8 billion deal to acquire Pharmasset ($VRUS) after CSO Norbert Bischofberger told analysts yesterday evening that PSI-7977 Read more...
Latest Headlines
- January 9, 2012
- December 23, 2011
- December 16, 2011
- December 14, 2011
- November 23, 2011
- November 22, 2011
- November 9, 2011
- October 10, 2011
- September 30, 2011
- May 4, 2010
- April 20, 2009
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
